|

Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

RECRUITINGSponsored by Seung-Jung Park
Actively Recruiting
SponsorSeung-Jung Park
Started2009-01
Est. completion2030-12
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT01186133

Summary

The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* coronary disease amenable to percutaneous coronary intervention (PCI)
* no clinical and lesion limitations

Exclusion Criteria:

* patients with a mixture of several DES
* terminal illness with life expectancy less than 1 year
* patients with cardiogenic shock

Conditions3

Coronary Artery DiseaseHeart DiseasePercutaneous Transluminal Coronary Angioplasty

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.